Through the partnership, Second Genome will pair its sg-4-sight discovery engine with Arena’s Cultivate clinical trial to identify microbiome biomarkers in order to “inform patient stratification and optimize potential treatments.”
Arena’s Cultivate trial is a clinical trial of the efficacy and safety of etrasimod, a drug candidate for patients with Crohn’s disease.
“There is substantial evidence that gut microbiome is intricately involved in therapy response in gastrointestinal diseases,” said Amit Munshi, president and CEO of Arena Pharmaceuticals. “We are pleased to collaborate with Second Genome to discover microbiome biomarkers predictive of clinical response.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
